Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Quadrimeningo 50mcg Injection

Prescription Icon
Prescription Required

Marketer

Bio-Med Pvt Ltd

Salt Composition

Meningococcal Vaccine (Group A, C, Y & W-135) (50mcg)

Overview Quadrimeningo 50mcg Injection

Meningococcal disease prophylaxis is achieved with Quadrimeningo 50mcg Injection. This vaccine provides active immunization against invasive meningococcal disease stemming from *Neisseria meningitidis* serogroups A, C, Y, and W-135. Recommended for infants (from two months), children, adolescents, and adults, its administration follows official guidelines. Always administered by a medical professional, self-injection is strictly prohibited. A complete vaccination course is crucial for optimal effectiveness. Commonly reported side effects include injection site discomfort (pain, swelling, redness), nausea, headache, drowsiness, irritability, general malaise, and muscle pain. Persistent or worsening side effects warrant immediate medical attention; your doctor can offer strategies for symptom management. Prior to vaccination, disclose any existing health conditions or medications to your physician to ensure safety. Pregnant or breastfeeding individuals should consult their doctor before vaccination.

Uses of Quadrimeningo 50mcg Injection

Averting Meningococcal Illness

Major Benefits of Quadrimeningo 50mcg Injection:

This medication will be administered by your healthcare provider; self-medication is strictly prohibited.

Common Side effects of Quadrimeningo 50mcg Injection:

  • Injection site reaction
  • Sleepiness
  • Nausea
  • Headache
  • Irritation
  • Muscle pain

How to use Quadrimeningo 50mcg Injection:

This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.

How Quadrimeningo 50mcg Injection works:

Quadrimeningo 50mcg Injection is a vaccine prompting antibody production. It achieves this by triggering a benign, subclinical infection that stimulates the immune system to generate protective proteins against subsequent exposure to the targeted pathogen.

SAFETY ADVICE

AlcoholAlcoholCONSULT YOUR DOCTOR

Alcohol consumption alongside Quadrimeningo 50mcg Injection is of uncertain safety. Seek medical advice before combining them.

PregnancyPregnancySAFE IF PRESCRIBED

The 50mcg Quadrimeningo Injection is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or absent negative impacts on fetal development; nevertheless, data from human trials remain scarce.

Breast feedingBreast feedingSAFE IF PRESCRIBED

The use of Quadrimeningo 50mcg Injection while breastfeeding is likely safe. Available human data indicates minimal risk to the infant.

DrivingDrivingSAFE

Administering a 50mcg Quadrimeningo injection typically has no impact on driving capabilities.

KidneyKidneyCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Quadrimeningo 50mcg Injection to individuals with renal impairment. Physician consultation is advised.

LiverLiverSAFE IF PRESCRIBED

The use of Quadrimeningo 50mcg Injection in patients with liver disease appears to pose minimal risk. Existing evidence indicates that dosage modification may not be necessary for this population. However, physician consultation is recommended.

What if you forget to take Quadrimeningo 50mcg Injection :

Omit a dose of Quadrimeningo 50mcg Injection? Seek medical advice immediately.

Facts to Know About Quadrimeningo 50mcg Injection

LabelValue
Type of Compound Immunizations
Potential for Dependence None.
Type of Medication Immunizations

FAQs on Quadrimeningo 50mcg Injection

The injectable vaccine Quadrimeningo, 50 mcg, provides active immunity against invasive meningococcal disease stemming from *Neisseria meningitidis* serogroups A, C, Y, and W-135. Its use is licensed for individuals aged 2 months to 55 years inclusive.
Patients with a history of hypersensitivity to Quadrimeningo 50mcg Injection components or related medications should not receive this injection. Allergic reactions can manifest as urticaria, respiratory distress, or facial/lingual edema. Prior medication allergies should be disclosed to the prescribing physician.
Individuals aged 15 to 55 facing persistent meningococcal disease risk may receive a single booster injection of 50 mcg Quadrimeningo, provided at least four years have elapsed since their last dose. Consult a physician for any uncertainties.
Quadrimeningo 50mcg Injection is administered solely by qualified medical personnel, never by the patient themselves. The injection is typically intramuscular, into the upper arm, though the thigh may be used for pediatric patients. Strict adherence to physician's instructions maximizes the therapeutic effect of Quadrimeningo 50mcg Injection.
Quadrimeningo 50mcg Injection does not induce meningococcal disease. Instead, it stimulates the body's production of protective antibodies, enabling a more effective immune response to future meningococcal exposure.
Quadrimeningo 50mcg Injec...
534
MRP 650
17% off